SeLux Diagnostics is a developer of the next-generation phenotyping platform that enables personalized antibiotic therapies for patients.
SeLux Diagnostics is a developer of the Next-Generation Phenotyping (NGP) platform that enables personalized antibiotic therapies for patients.The company was founded in 2014 and is based in Charlestown, MA.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 19, 2021 | Grant | $2.80M | 1 |
National Institutes of Health
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
National Institutes of Health
|
Yes | Grant |